Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1717 to 1722 of 1722 entries
Sorted by: Best Match Show Resources per page
The Cardiovascular Risk of Proton Pump Inhibitors and the Dangers of Polypharmacy.

Mayo Clinic proceedings

Malik N, Weintraub WS.
PMID: 34607632
Mayo Clin Proc. 2021 Oct;96(10):2511-2513. doi: 10.1016/j.mayocp.2021.08.017.

No abstract available.

Cite
Malik N, Weintraub WS. The Cardiovascular Risk of Proton Pump Inhibitors and the Dangers of Polypharmacy. Mayo Clin Proc. 2021;96(10):2511-2513doi: 10.1016/j.mayocp.2021.08.017.
Malik, N., & Weintraub, W. S. (2021). The Cardiovascular Risk of Proton Pump Inhibitors and the Dangers of Polypharmacy. Mayo Clinic proceedings, 96(10), 2511-2513. https://doi.org/10.1016/j.mayocp.2021.08.017
Malik, Nitin, and Weintraub, William S. "The Cardiovascular Risk of Proton Pump Inhibitors and the Dangers of Polypharmacy." Mayo Clinic proceedings vol. 96,10 (2021): 2511-2513. doi: https://doi.org/10.1016/j.mayocp.2021.08.017
Malik N, Weintraub WS. The Cardiovascular Risk of Proton Pump Inhibitors and the Dangers of Polypharmacy. Mayo Clin Proc. 2021 Oct;96(10):2511-2513. doi: 10.1016/j.mayocp.2021.08.017. PMID: 34607632.
Copy Download .nbib Format: NLM
Association of proton pump inhibitor use with the development of febrile neutropenia in lymphoma patients.

Expert review of hematology

Hazzan R, Darawsha U, Neeman Z, Aviv A.
PMID: 33899663
Expert Rev Hematol. 2021 May;14(5):503-507. doi: 10.1080/17474086.2021.1920011. Epub 2021 Apr 26.

No abstract available.

Cite
Hazzan R, Darawsha U, Neeman Z, et al. Association of proton pump inhibitor use with the development of febrile neutropenia in lymphoma patients. Expert Rev Hematol. 2021;14(5):503-507doi: 10.1080/17474086.2021.1920011.
Hazzan, R., Darawsha, U., Neeman, Z., & Aviv, A. (2021). Association of proton pump inhibitor use with the development of febrile neutropenia in lymphoma patients. Expert review of hematology, 14(5), 503-507. https://doi.org/10.1080/17474086.2021.1920011
Hazzan, Rawi, et al. "Association of proton pump inhibitor use with the development of febrile neutropenia in lymphoma patients." Expert review of hematology vol. 14,5 (2021): 503-507. doi: https://doi.org/10.1080/17474086.2021.1920011
Hazzan R, Darawsha U, Neeman Z, Aviv A. Association of proton pump inhibitor use with the development of febrile neutropenia in lymphoma patients. Expert Rev Hematol. 2021 May;14(5):503-507. doi: 10.1080/17474086.2021.1920011. Epub 2021 Apr 26. PMID: 33899663.
Copy Download .nbib Format: NLM
Adverse reactions related to proton pump inhibitors in pediatric population: an analysis of spontaneous reporting data.

Expert opinion on drug safety

Dipasquale V, Cicala G, Laganà F, Cutroneo P, Felicetti P, Potenza S, Trimarchi G, Spina E, Romano C.
PMID: 34494498
Expert Opin Drug Saf. 2022 Jan;21(1):127-132. doi: 10.1080/14740338.2021.1978975. Epub 2021 Sep 20.

BACKGROUND: The use of proton pump inhibitors (PPIs) has increased in the last 10 years in children. Data regarding their safety profile are limited. The aim of this study was to analyze data from the Italian spontaneous reporting system...

Cite
Dipasquale V, Cicala G, Laganà F, et al. Adverse reactions related to proton pump inhibitors in pediatric population: an analysis of spontaneous reporting data. Expert Opin Drug Saf. 2021;21(1):127-132doi: 10.1080/14740338.2021.1978975.
Dipasquale, V., Cicala, G., Laganà, F., Cutroneo, P., Felicetti, P., Potenza, S., Trimarchi, G., Spina, E., & Romano, C. (2022). Adverse reactions related to proton pump inhibitors in pediatric population: an analysis of spontaneous reporting data. Expert opinion on drug safety, 21(1), 127-132. https://doi.org/10.1080/14740338.2021.1978975
Dipasquale, Valeria, et al. "Adverse reactions related to proton pump inhibitors in pediatric population: an analysis of spontaneous reporting data." Expert opinion on drug safety vol. 21,1 (2022): 127-132. doi: https://doi.org/10.1080/14740338.2021.1978975
Dipasquale V, Cicala G, Laganà F, Cutroneo P, Felicetti P, Potenza S, Trimarchi G, Spina E, Romano C. Adverse reactions related to proton pump inhibitors in pediatric population: an analysis of spontaneous reporting data. Expert Opin Drug Saf. 2022 Jan;21(1):127-132. doi: 10.1080/14740338.2021.1978975. Epub 2021 Sep 20. PMID: 34494498.
Copy Download .nbib Format: NLM
Association of Common Medications and the Risk of Early-Onset Gastric Cancer: A Population-Based Matched Study.

Journal of cancer epidemiology

MacArthur TA, Harmsen WS, Mandrekar J, Abraha F, Grotz TE.
PMID: 34899912
J Cancer Epidemiol. 2021 Dec 02;2021:2670502. doi: 10.1155/2021/2670502. eCollection 2021.

BACKGROUND: Early-onset gastric cancer (EOGC, age ≤ 60 years at diagnosis) now comprises >30% of new gastric cancers in the United States. It is hypothesized that chronic acid suppression with proton-pump inhibitors (PPIs) may promote tumorigenesis, while other medications...

Cite
MacArthur TA, Harmsen WS, Mandrekar J, et al. Association of Common Medications and the Risk of Early-Onset Gastric Cancer: A Population-Based Matched Study. J Cancer Epidemiol. 2021;2021:2670502doi: 10.1155/2021/2670502.
MacArthur, T. A., Harmsen, W. S., Mandrekar, J., Abraha, F., & Grotz, T. E. (2021). Association of Common Medications and the Risk of Early-Onset Gastric Cancer: A Population-Based Matched Study. Journal of cancer epidemiology, 20212670502. https://doi.org/10.1155/2021/2670502
MacArthur, Taleen A, et al. "Association of Common Medications and the Risk of Early-Onset Gastric Cancer: A Population-Based Matched Study." Journal of cancer epidemiology vol. 2021 (2021): 2670502. doi: https://doi.org/10.1155/2021/2670502
MacArthur TA, Harmsen WS, Mandrekar J, Abraha F, Grotz TE. Association of Common Medications and the Risk of Early-Onset Gastric Cancer: A Population-Based Matched Study. J Cancer Epidemiol. 2021 Dec 02;2021:2670502. doi: 10.1155/2021/2670502. eCollection 2021. PMID: 34899912; PMCID: PMC8660238.
Copy Download .nbib Format: NLM
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding.

The Cochrane database of systematic reviews

Kanno T, Yuan Y, Tse F, Howden CW, Moayyedi P, Leontiadis GI.
PMID: 34995368
Cochrane Database Syst Rev. 2022 Jan 07;1:CD005415. doi: 10.1002/14651858.CD005415.pub4.

BACKGROUND: Upper gastrointestinal (GI) bleeding is a common reason for emergency hospital admission. Proton pump inhibitors (PPIs) reduce gastric acid production and are used to manage upper GI bleeding. However, there is conflicting evidence regarding the clinical efficacy of...

Cite
Kanno T, Yuan Y, Tse F, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2022;1:CD005415doi: 10.1002/14651858.CD005415.pub4.
Kanno, T., Yuan, Y., Tse, F., Howden, C. W., Moayyedi, P., & Leontiadis, G. I. (2022). Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. The Cochrane database of systematic reviews, 1CD005415. https://doi.org/10.1002/14651858.CD005415.pub4
Kanno, Takeshi, et al. "Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding." The Cochrane database of systematic reviews vol. 1 (2022): CD005415. doi: https://doi.org/10.1002/14651858.CD005415.pub4
Kanno T, Yuan Y, Tse F, Howden CW, Moayyedi P, Leontiadis GI. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2022 Jan 07;1:CD005415. doi: 10.1002/14651858.CD005415.pub4. PMID: 34995368; PMCID: PMC8741303.
Copy Download .nbib Format: NLM
A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease.

Journal of neurogastroenterology and motility

Jung DH, Huh CW, Lee SK, Park JC, Shin SK, Lee YC.
PMID: 33795539
J Neurogastroenterol Motil. 2021 Apr 30;27(2):165-175. doi: 10.5056/jnm20161.

BACKGROUND/AIMS: Prokinetics can be used for treating patients with gastroesophageal reflux disease (GERD), who exhibit suboptimal response to proton pump inhibitor (PPI) treatment. We conducted a systematic review to assess the potential benefits of combination treatment with PPI plus...

Cite
Jung DH, Huh CW, Lee SK, et al. A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2021;27(2):165-175doi: 10.5056/jnm20161.
Jung, D. H., Huh, C. W., Lee, S. K., Park, J. C., Shin, S. K., & Lee, Y. C. (2021). A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease. Journal of neurogastroenterology and motility, 27(2), 165-175. https://doi.org/10.5056/jnm20161
Jung, Da Hyun, et al. "A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease." Journal of neurogastroenterology and motility vol. 27,2 (2021): 165-175. doi: https://doi.org/10.5056/jnm20161
Jung DH, Huh CW, Lee SK, Park JC, Shin SK, Lee YC. A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2021 Apr 30;27(2):165-175. doi: 10.5056/jnm20161. PMID: 33795539; PMCID: PMC8026378.
Copy Download .nbib Format: NLM
Showing 1717 to 1722 of 1722 entries